Evidence map›Paper›PMID 24487026›Full record

ArticleDiabetes2014

Reduced incorporation of fatty acids into triacylglycerol in myotubes from obese individuals with type 2 diabetes.

Lauren M Sparks, Madeleen Bosma, Bram Brouwers, Tineke van de Weijer, Lena Bilet, Gert Schaart, Esther Moonen-Kornips, Thomas O Eichmann, Achim Lass, Matthijs K C Hesselink and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Diabetes, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 3 countries.

Lauren M Sparks *Department of Human Biology, NUTRIM-School for Nutrition, Toxicology and Metabolism, Departments of Human Biology, Maastricht University Medical Center, Maastricht, the Netherlands.
Madeleen Bosma *Department of Human Biology, NUTRIM-School for Nutrition, Toxicology and Metabolism, Departments of Human Biology, Maastricht University Medical Center, Maastricht, the Netherlands.
Bram BrouwersDepartment of Human Biology, NUTRIM-School for Nutrition, Toxicology and Metabolism, Departments of Human Biology, Maastricht University Medical Center, Maastricht, the Netherlands.
Tineke van de WeijerDepartment of Human Biology, NUTRIM-School for Nutrition, Toxicology and Metabolism, Departments of Human Biology, Maastricht University Medical Center, Maastricht, the Netherlands.
Lena BiletDepartment of Human Biology, NUTRIM-School for Nutrition, Toxicology and Metabolism, Departments of Human Biology, Maastricht University Medical Center, Maastricht, the Netherlands.
Gert SchaartDepartment of Human Movement Sciences, NUTRIM-School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, Maastricht, the Netherlands.
Esther Moonen-KornipsDepartment of Human Biology, NUTRIM-School for Nutrition, Toxicology and Metabolism, Departments of Human Biology, Maastricht University Medical Center, Maastricht, the Netherlands.
Thomas O EichmannInstitute of Molecular Biosciences, University of Graz, Graz, Austria.
Achim LassInstitute of Molecular Biosciences, University of Graz, Graz, Austria.
Matthijs K C Hesselink *Department of Human Movement Sciences, NUTRIM-School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, Maastricht, the Netherlands.
Patrick Schrauwen *Department of Human Biology, NUTRIM-School for Nutrition, Toxicology and Metabolism, Departments of Human Biology, Maastricht University Medical Center, Maastricht, the Netherlands.
Maastricht University · NLUniversity of Graz · AT

Funding

Austrian Science Fund FWF P 25193
6 · The paper itself

Abstract

Altered skeletal muscle lipid metabolism is a hallmark feature of type 2 diabetes (T2D). We investigated muscle lipid turnover in T2D versus BMI-matched control subjects (controls) and examined whether putative in vivo differences would be preserved in the myotubes. Male obese T2D individuals (n = 6) and BMI-matched controls (n = 6) underwent a hyperinsulinemic-euglycemic clamp, VO2max test, dual-energy X-ray absorptiometry scan, underwater weighing, and muscle biopsy of the vastus lateralis. (14)C-palmitate and (14)C-oleate oxidation rates and incorporation into lipids were measured in muscle tissue as well as in primary myotubes. Palmitate oxidation (controls: 0.99 ± 0.17 nmol/mg protein; T2D: 0.53 ± 0.07 nmol/mg protein; P = 0.03) and incorporation of fatty acids (FAs) into triacylglycerol (TAG) (controls: 0.45 ± 0.13 nmol/mg protein; T2D: 0.11 ± 0.02 nmol/mg protein; P = 0.047) were significantly reduced in muscle homogenates of T2D. These reductions were not retained for palmitate oxidation in primary myotubes (P = 0.38); however, incorporation of FAs into TAG was lower in T2D (P = 0.03 for oleate and P = 0.11 for palmitate), with a strong correlation of TAG incorporation between muscle tissue and primary myotubes (r = 0.848, P = 0.008). The data indicate that the ability to incorporate FAs into TAG is an intrinsic feature of human muscle cells that is reduced in individuals with T2D.

Indexed as

AdultDiabetes Mellitus, Type 2Fatty AcidsGlucoseHumansLipid MetabolismMaleMiddle AgedMuscle Fibers, SkeletalMuscle, SkeletalObesityPalmitatesTriglyceridesFatty AcidsGlucosePalmitatesTriglycerides

Identifiers

PMID24487026
PMCPMC4023412
OpenAlexW2136481623

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.